Schedule 13G ownership disclosure

Tenax Therapeutics, Inc.

Common Stock, par value $0.0001 per share · CUSIP: 88032L605

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Lind Global Fund II LP

    Shares: 442,480 · Class: 6.62%

  • Lind Global Partners II LLC

    Shares: 442,480 · Class: 6.62%

  • EASTON JEFF

    Shares: 442,480 · Class: 6.62%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000929638-26-000667
Form type
SCHEDULE 13G/A
Filer
Lind Global Fund II LP
CIK
CIK 1871665
Filed
Feb 17, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub